Amenamevir is a selective anti-herpesvirus drug that exerts its therapeutic effect by inhibiting viral DNA replication.
I. Indications
1. Herpes Zoster
(1) Indicated for the treatment of herpes zoster in adults.
(2) It is recommended to initiate treatment as early as within 5 days after the onset of the rash. Take 400 mg once daily after meals, and the treatment course is 7 days in principle.
2. Recurrent Herpes Simplex
(1) Indicated for adult patients with recurrent herpes simplex (including oral herpes and genital herpes).
(2) Patients are required to accurately recognize the initial symptoms (such as local discomfort, burning sensation, and pruritus), and take a single dose of 1200 mg within 6 hours after the onset of symptoms and before the appearance of the rash.
II. Contraindications
1. Allergic History
Patients with a history of allergy to any component of this preparation are contraindicated for use.
2. Specific Drug Combinations
(1) Patients taking rifampicin are contraindicated for use.
(2) Rifampicin can significantly reduce the blood concentration of amenamevir, leading to a decrease in therapeutic efficacy.
3. Contraindications for Special Populations
Pregnant and lactating women should not use the drug on their own in principle, and it should be considered only after strict evaluation by a doctor.
III. Contraindicated Foods and Drug Interactions
1. Avoid Concomitant Use with St. John's Wort
Foods or supplements containing St. John's Wort can induce CYP3A enzymes, accelerate the metabolism of amenamevir, reduce its blood concentration, and weaken the therapeutic effect.
2. Avoid Concomitant Use with Grapefruit
Grapefruit juice may affect drug metabolism, leading to a decrease in the blood concentration of amenamevir. It is recommended to avoid drinking it during the medication period.
3. Attention to Other Drug Interactions
(1) When this product is combined with CYP3A inhibitors (such as clarithromycin and ritonavir), its blood concentration may increase, and caution is required.
(2) When combined with CYP3A inducers (such as carbamazepine and phenobarbital), the therapeutic effect may decrease.
IV. Medication for Special Populations
1. Immunocompromised Patients
For patients with immunocompromise such as malignant tumors and autoimmune diseases, the efficacy and safety of this product have not been established, and it should be used with caution.
2. Pregnant Women
(1) It can only be used when the therapeutic benefit is significantly greater than the risk.
(2) Animal experiments have shown that this product can cross the placenta, so pregnant women should avoid using it on their own.
3. Lactating Women
(1) The decision to continue or suspend breastfeeding should be made by comprehensively considering the necessity of treatment and the benefits of breastfeeding.
(2) Animal experiments have shown that this product can be secreted into breast milk.
4. Children
Clinical studies in children have not been conducted, and the safety and efficacy are unclear. Its use is not recommended.
5. Elderly Patients
(1) The physiological functions of elderly patients generally decline, especially renal function may be impaired.
(2) Monitoring should be carried out during medication, and the dosage should be adjusted if necessary.
6. Patients with Renal Insufficiency
(1) The drug exposure increases in patients with mild to moderate renal insufficiency.
(2) The area under the concentration-time curve (AUC) of the drug is significantly increased in patients with severe renal insufficiency, and it should be used under the guidance of a doctor with caution.
7. Hemodialysis Patients
This product can be partially cleared by hemodialysis, but hemodialysis has a limited effect on the elimination half-life of the drug in the body. The medication should be comprehensively evaluated based on clinical conditions.
8. Patients with Hepatic Insufficiency
After administration in patients with moderate hepatic insufficiency, the drug exposure is similar to that in healthy people, but it still needs to be used under the guidance of a doctor.
